CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $254.96M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
254.96MUSDvs all stocks (USD)
Revenue (TTM)
7.49MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.5080xvs all stocks
52-Week Change
152.42%vs all stocks
Market Capitalization
254.96MUSDvs all stocks (USD)
Enterprise Value
154.83MUSDvs all stocks (USD)
Forward P/E
-5.51xvs Biotechnology peers
Price to Sales (TTM)
34.02xvs Biotechnology peers
Enterprise to Revenue
20.66xvs Biotechnology peers
Enterprise to EBITDA
-3.63xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-209.12%vs Biotechnology peers
Return on Assets (TTM)
-22.82%vs Biotechnology peers
Revenue (TTM)
7.49MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.8050USDUpdated Jul 19, 2026Quarterly Revenue Growth
408.60%vs Biotechnology peers
Gross Profit (TTM)
-24.64MUSDvs all stocks (USD)
EBITDA (TTM)
135.09MUSDvs all stocks (USD)
Net Income (TTM)
-342.56MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
408.65%vs Biotechnology peers
Operating Cash Flow (TTM)
-33.46MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.11MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.48MUSDFY2025 · Dec 31, 2025Operating Income
-42.09MUSDvs all stocks (USD)
Pre-tax Income
-242.03MUSDFY2025 · Dec 31, 2025Net Income
-242.03MUSDFY2025 · Dec 31, 2025EBIT
-42.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
135.09MUSDFY2025 · Dec 31, 2025Research & Development
29.36MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.02MUSDFY2025 · Dec 31, 2025EPS (Basic)
-32.37USDFY2025 · Dec 31, 2025EPS (Diluted)
-32.37USDFY2025 · Dec 31, 2025Basic Shares Outstanding
7.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
7.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-242.03MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-164.82MUSDFY2025 · Dec 31, 2025Free Cash Flow
-164.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
89.93MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-242.03MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
537.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
72.12MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.33MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
142.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-128.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-128.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
83.78MUSDFY2025 · Dec 31, 2025Shares Outstanding
11.49MSharesUpdated Jul 19, 2026Float Shares
5.09MSharesUpdated Jul 19, 2026Shares Short
709.76KSharesUpdated Jul 19, 2026Short Ratio
4.38daysvs all stocks
Short % of Shares Outstanding
11.12%vs all stocks
% Held by Insiders
3.18%vs all stocks
% Held by Institutions
102.32%vs all stocks
Total Cash (MRQ)
106.91MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.21USDUpdated Jul 19, 2026Total Debt (MRQ)
6.78MUSDvs all stocks (USD)
Current Ratio (MRQ)
11.91xvs Biotechnology peers
Book Value per Share (MRQ)
-24.21USDUpdated Jul 19, 2026Total Assets
98.73MUSDvs all stocks (USD)
Total Current Assets
91.56MUSDFY2025 · Dec 31, 2025Total Liabilities
286.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
7.17MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
276.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
89.25MUSDFY2025 · Dec 31, 2025Accounts Receivable
0.00USDFY2025 · Dec 31, 2025Accounts Payable
728.00KUSDFY2025 · Dec 31, 2025Short-term Debt
1.29MUSDFY2025 · Dec 31, 2025Other Current Liabilities
289.00KUSDFY2025 · Dec 31, 2025Long-term Debt
5.35MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
158.66MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-527.28MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-187.76MUSDvs all stocks (USD)
52-Week Low
8.21USDUpdated Jul 19, 202652-Week High
35.00USDUpdated Jul 19, 202652-Week Change
152.42%vs all stocks
Beta
0.5080xvs all stocks
50-Day MA
25.06USDUpdated Jul 19, 2026200-Day MA
22.45USDUpdated Jul 19, 2026Avg 10-Day Volume
170.49KSharesUpdated Jul 19, 2026Avg 30-Day Volume
167.08KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-36.59USDUpdated Jul 19, 2026Other Income / Expense
-202.95MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $254.96M, lower than 95% of all stocks globallySignificant
Market cap (USD): 254,963,747Global P5: 269,387,740.27
Revenue is $7.49M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,494,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Immunome Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Kopin Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC